Opthea Limited (NASDAQ:OPT – Get Rating) – Stock analysts at Oppenheimer increased their FY2023 earnings per share estimates for shares of Opthea in a report issued on Monday, March 13th. Oppenheimer analyst H. Singh now anticipates that the company will post earnings per share of ($1.55) for the year, up from their prior estimate of ($1.70). Oppenheimer currently has a “Outperform” rating and a $31.00 price target on the stock. The consensus estimate for Opthea’s current full-year earnings is ($2.17) per share. Oppenheimer also issued estimates for Opthea’s FY2024 earnings at ($1.55) EPS, FY2025 earnings at ($1.20) EPS, FY2026 earnings at $0.25 EPS and FY2027 earnings at $4.30 EPS.
A number of other equities research analysts have also weighed in on the company. Citigroup decreased their target price on Opthea from $24.00 to $22.00 in a research report on Thursday, March 9th. HC Wainwright reaffirmed a “buy” rating and set a $14.00 target price on shares of Opthea in a research report on Friday, February 24th.
Opthea Price Performance
Institutional Inflows and Outflows
An institutional investor recently raised its position in Opthea stock. Victory Capital Management Inc. increased its holdings in shares of Opthea Limited (NASDAQ:OPT – Get Rating) by 2.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,643,585 shares of the company’s stock after buying an additional 39,358 shares during the quarter. Victory Capital Management Inc. owned 2.83% of Opthea worth $10,174,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 13.85% of the stock is currently owned by institutional investors and hedge funds.
Opthea Company Profile
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
- Get a free copy of the StockNews.com research report on Opthea (OPT)
- Don’t Miss Out: $2 Trillion Could be Headed to the Banking Sector
- A Weakening Economy Suggests Caution Before Buying Five Below
- Williams-Sonoma: Time To Buy At Rock-Bottom Prices
- Why DraftKings Could Keep Outperforming in 2023
- Charles Schwab And The Safest 30% You Can Make This Year
Receive News & Ratings for Opthea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opthea and related companies with MarketBeat.com's FREE daily email newsletter.